Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-25T16:42:41.229Z Has data issue: false hasContentIssue false
  • English
  • Français

Do findings from new trials for schizophrenia fit with existing evidence: not duped … just beguiled?

Published online by Cambridge University Press:  18 May 2011

Clive E. Adams  and
Mahesh Jayaram
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

No treatment has caused a greater revolution in the treatment of people with schizophrenia than chlorpromazine. The new generation of drugs has been embraced by psychiatry with an enthusiasm fostered by the unmet needs of both patients and industry. Recent, independently funded trials have highlighted already existing data illustrating how the new antipsychotics drugs are an additional advance but not a revolution. In this story there are lessons for psychiatry to opt for science rather than seduction.

Type
Editorials
Information
Epidemiology and Psychiatric Sciences , Volume 16 , Issue 3 , September 2007 , pp. 199 - 202
Copyright
Copyright © Cambridge University Press 2007

References

REFERENCES

Adams, C.E. (2002). Schizophrenia trials: past, present and future. Epidemiologia e Psichiatria Sociale 11, 144–1451.CrossRefGoogle ScholarPubMed
Adams, C.E., Tharyan, P., Coutinho, E.S. & Stroup, T.S. (2006). The schiz-ophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. British Journal of Psychiatry 189, 391–392.CrossRefGoogle Scholar
Begg, C., M, Cho, Eastwood, S., Horton, R., Moher, D., Olkin, I., Pitkin, R., Rennie, D., Schulz, K.F., Simel, D. & Stroup, D.F. (1996). Improving the quality of reporting of randomized controlled trials. The CONSORT statement. Journal of American Medical Association 276, 637–639.CrossRefGoogle ScholarPubMed
Centre for Reviews and Dissemination (2007). Drug treatments for schizophrenia Effective Health Care Bulletin. Retrieved June 4, 2007, from http://www.york.ac.uk/inst/crd/ehc56.htmGoogle Scholar
Duggan, L., M, Fenton, Dardennes, R.M., El-Dosoky, A. & Indran, S. (2000). Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.CrossRefGoogle Scholar
Duggan, L., Fenton, M., Rathbone, J., Dardennes, R., El-Dosoky, A. & Indran, S. (2005). Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.CrossRefGoogle Scholar
Dyer, O. (2007). Lilly investigated in US over the marketing of olanzapine. British Medical Journal 334, 171.Google ScholarPubMed
El-Sayeh, H.G. & Morganti, C. (2006). Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.CrossRefGoogle Scholar
Freeman, H. (1958). The tranquilising drugs. In Schizophrenia: A Review of the Syndrome (ed. Bellak, L.). Logos Press: New York.Google Scholar
Hafner, H. (2004). Schizophrenia: still Kraepelin's dementia praecox? Epidemiologia e Psichiatria Sociale 13, 99–112.CrossRefGoogle ScholarPubMed
Hartung, B., Wada, M., Laux, G. & Leucht, S. (2005). Perphenazine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 1.CrossRefGoogle Scholar
Heres, S., Davis, J., Maino, K., Jetzinger, E., Kissling, W. & Leucht, S. (2006). Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry 163, 185–194.CrossRefGoogle ScholarPubMed
Hotopf, M., Churchill, R. & Lewis, G. (1999). Pragmatic randomised controlled trials in psychiatry. British Journal of Psychiatry 175,217–223.CrossRefGoogle ScholarPubMed
Jayaram, M.B., Hosalli, P. & Stroup, S. (2006). Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.CrossRefGoogle Scholar
Jones, P.B., Barnes, T.R., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K.P., Murray, R.M., Markwick, A. & Lewis, S.W. (2006). Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63, 1079–12087.CrossRefGoogle Scholar
Joy, C.B., Adams, C.E. & Lawrie, S.M. (2006). Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 4.Google Scholar
Kane, J., Honigfeld, G., Singer, J. & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789–796.CrossRefGoogle ScholarPubMed
Kennedy, E., Song, F., Hunter, R., Clarke, A. & Gilbody, S. (2000). Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.Google Scholar
Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S., Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J., Hsiao, J.K. & Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209–1223.CrossRefGoogle ScholarPubMed
Marques, L.O., Lima, M.S. & Soares, B.G. (2004). Trifluoperazine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 1.CrossRefGoogle Scholar
Matar, H. & Almerie, M. (2007). Oral fluphenazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, Issue 1.CrossRefGoogle Scholar
Montgomery, J.H., Byerly, M., Carmody, T., Li, B., Miller, D.R., Varghese, F. & Holland, R. (2004). An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Controlled Clinical Trials 25, 598–612.CrossRefGoogle ScholarPubMed
Mota, N.E., Lima, M.S. & Soares, B.G. (2002). Amisulpride for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.Google Scholar
NHS National Institute for Clinical Excellence (2007). Schizophrenia: NICE guideline. Retrieved June 4, 2007, from http://www.nice.org. uk/guidance/CG 1/niceguidance/pdf/EnglishGoogle Scholar
Soares, B.G., Fenton, M. & Chue, P. (2000). Sulphide for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.Google Scholar
Srisurapanont, M., Maneeton, B. & Maneeton, N. (2004). Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.CrossRefGoogle Scholar
Thornley, B. & Adams, C. (1998). Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal 317, 1181–1184.CrossRefGoogle ScholarPubMed
Thornley, B., Rathbone, J., Adams, C.E. & Awad, G. (2003). Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.CrossRefGoogle Scholar
Turner, T. (2007). Chlorpromazine: unlocking psychosis. British Medical Journal 334, Suppl 1, s7.CrossRefGoogle ScholarPubMed
Tuunainen, A., Wahlbeck, K. & Gilbody, S.M. (2000). Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.CrossRefGoogle Scholar
Vedantam, S. (2006). In antipsychotics, newer isn't better drug find shocks researchers. Washington Post, Tuesday, October 3, 2006. Retrieved June 4, 2007, from http://www.washingtonpost.com/wpdyn/content/article/2006/10/02/AR2006100201378.htmlGoogle Scholar
Wahlbeck, K., Cheine, M. & Essali, M.A. (2000). Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews, Issue 2.Google Scholar